Natco Pharma Share Price
829.35-8.95 (-1.07%)
-4.89% past 1 Year
Natco Pharma is engaged in the business of pharmaceuticals and agricultural chemicals which comprises research and development, manufacturing and selling of bulk drugs, finished dosage formulations. The Company has manufacturing
Corporate filings & documents
Announcements
Investor Meet
1 day agoInvestor Meet
1 day agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Durga Devi Nannapaneni
1 week agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Durga Devi Nannapaneni
1 week agoPress Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding the investment in eGenesis Inc.
1 week agoPress Release & Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015 regarding the investment in eGenesis Inc.
1 week agoIntimation of Investor Meet
1 week agoIntimation of Investor Meet
1 week agoConclusion of US FDS Inspection at our Visakhapatnam Andhra Pradesh Finished Dosage (FDF) Unit
1 week agoConclusion of US FDS Inspection at our Visakhapatnam Andhra Pradesh Finished Dosage (FDF) Unit
1 week agoInvestor Meet
2 weeks agoInvestor Meet
2 weeks agoInvestor Presentation
2 weeks agoInvestor Presentation
2 weeks agoQ1FY2026-27 Transcript for the Earnings call held on 14th August 2026
2 weeks agoQ1FY2026-27 Transcript for the Earnings call held on 14th August 2026
2 weeks agoIntimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited
2 weeks agoIntimation of Investors meeting organised by Nuvama Wealth Management Limited and ICICI Securities Limited
2 weeks agoNewspaper Publication for the Un-Audited Financial Results for the quarter ended June 30 2026 and declaration of Interim Dividend for the FY ending 2026-27.
2 weeks agoNewspaper Publication for the Un-Audited Financial Results for the quarter ended June 30 2026 and declaration of Interim Dividend for the FY ending 2026-27.
2 weeks agoWeblink of Audio Transcript for the earnings call held on 14th August 2026 for Q1FY2026-27
2 weeks agoWeblink of Audio Transcript for the earnings call held on 14th August 2026 for Q1FY2026-27
2 weeks agoInvestor Presentation for the Q1FY27
2 weeks agoInvestor Presentation for the Q1FY27
2 weeks agoBoard of Directors at their Meeting held on today i.e. 14th August 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- each
2 weeks agoBoard of Directors at their Meeting held on today i.e. 14th August 2026 had declared Interim Dividend of Rs.1.50 (75%) for face value of Rs.2/- each
2 weeks agoOutcome of Board Meeting
2 weeks agoOutcome of Board Meeting
2 weeks agoThe Company will host an Earnings Call with Investors / Analysts on Friday the 14th August 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ended 30th June 2026
3 weeks agoThe Company will host an Earnings Call with Investors / Analysts on Friday the 14th August 2026 at 17:30 PM IST to discuss the Un-audited Financial Results of the Company for the quarter ended 30th June 2026
3 weeks agoNatco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Further to our earlier intimation dated August 6 2026 pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended this is to inform you that a meeting of the Board of Directors of the Company will be held on August 14 2026 to consider and evaluate proposals for raising funds through issuance of equity shares or other securities including by way of a public issue preferential issue rights issue private placement(s) qualified institutions placement(s) and/or any combination thereof or any other method as may be permitted in accordance with provisions of applicable laws subject to market conditions and receipt of regulatory statutory and other approvals as may be required
3 weeks agoNatco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Further to our earlier intimation dated August 6 2026 pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended this is to inform you that a meeting of the Board of Directors of the Company will be held on August 14 2026 to consider and evaluate proposals for raising funds through issuance of equity shares or other securities including by way of a public issue preferential issue rights issue private placement(s) qualified institutions placement(s) and/or any combination thereof or any other method as may be permitted in accordance with provisions of applicable laws subject to market conditions and receipt of regulatory statutory and other approvals as may be required
3 weeks agoNatco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Un-audited Financial Results for the quarter ended 30th June 2026 and declare Interim Dividend if any for the FY 2026-27
4 weeks agoNatco Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Un-audited Financial Results for the quarter ended 30th June 2026 and declare Interim Dividend if any for the FY 2026-27
4 weeks agoPress Release: NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA)
1 month agoPress Release: NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA)
1 month agoNatco Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram holdings Proprietary Limited
1 month agoNatco Pharma Limited completes acquisition of additional 13.25% stake in Adcock Ingram holdings Proprietary Limited
1 month agoOrder passed by Assistant Commissioner (ST)(FAC) Tenali Circle Tenali Andhra Pradesh
1 month agoOrder passed by Assistant Commissioner (ST)(FAC) Tenali Circle Tenali Andhra Pradesh
1 month agoCompliance Certificate under Reg.74(5) of SEBI (DP) Regulations 2018
1 month agoCompliance Certificate under Reg.74(5) of SEBI (DP) Regulations 2018
1 month agoOutcome of Board Meeting
1 month agoOutcome of Board Meeting
1 month agoDisclosure under Regulation 30 of SEBI (LODR) Regulations 2015
1 month agoDisclosure under Regulation 30 of SEBI (LODR) Regulations 2015
1 month agoSuperannuation of Mr. N. Malleswara Rao Vice President - Operations Pharma Division Kothur w.e.f. closure of business hours on 30th June 2026
2 months agoSuperannuation of Mr. N. Malleswara Rao Vice President - Operations Pharma Division Kothur w.e.f. closure of business hours on 30th June 2026
2 months agoClosure of Trading Window
2 months agoClosure of Trading Window
2 months agoConcalls & investor presentations
Aug 2026
May 2026
Feb 2026
Aug 2025
ConcallPresentation
Aug 2025
ConcallPresentation
May 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Feb 2025
ConcallPresentation
Nov 2024
ConcallPresentation
Nov 2024
ConcallPresentation
Aug 2024
ConcallPresentation
Aug 2024
ConcallPresentation
May 2024
ConcallPresentation
May 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Feb 2024
ConcallPresentation
Nov 2023
ConcallPresentation
Nov 2023
ConcallPresentation
Aug 2023
ConcallPresentation
Aug 2023
ConcallPresentation
May 2023
ConcallPresentation
May 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Feb 2023
ConcallPresentation
Nov 2022
ConcallPresentation
Nov 2022
ConcallPresentation
Aug 2022
ConcallPresentation
Aug 2022
ConcallPresentation
May 2022
ConcallPresentation
May 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Nov 2021
ConcallPresentation
Nov 2021
ConcallPresentation
Aug 2021
Jun 2021
ConcallPresentation
Jun 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Feb 2021
ConcallPresentation
Nov 2020
ConcallPresentation
Nov 2020
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-08-20
Dividend
1.5
2026-02-18
Dividend
1.5
2025-11-20
Dividend
1.5
2025-11-14
Demerger
Demerger
2025-08-19
Dividend
2.0
2025-02-18
Dividend
1.5
2024-11-27
Dividend
1.5
2024-08-23
Dividend
3.0
2024-02-26
Dividend
1.25
2023-11-24
Dividend
1.25
2023-08-22
Dividend
7.0
2023-02-21
Dividend
1.25
2022-11-21
Dividend
0.75
2022-08-19
Dividend
3.5
2022-02-24
Dividend
2.0
2021-08-24
Dividend
2.0
2021-02-22
Dividend
1.0
2020-11-24
Dividend
3.0
2020-08-21
Dividend
1.25
2020-06-26
Dividend
1.0
2020-02-24
Dividend
3.5
2019-11-21
Dividend
1.0
2019-08-22
Dividend
1.25
2019-06-06
Dividend
1.25
2019-02-21
Dividend
3.5
2018-08-20
Dividend
1.5
2018-02-15
Dividend
7.0
2017-08-16
Dividend
1.25
2017-02-23
Dividend
6.0
2016-08-19
Dividend
0.75
2016-02-22
Dividend
1.25
2015-11-26
Split
10:2
2015-02-24
Dividend
5.0
2014-02-24
Dividend
5.0
2013-02-22
Dividend
4.0
2012-02-22
Dividend
3.0
2011-02-24
Dividend
2.0
Company details
Registered office
Natco House Road No 2 Banjara Hills Hyderabad Telangana PIN: 500034 Tel No: 040-23547532 Fax No: 040-23548243 Email: [email protected] / [email protected] Internet: www.natcopharma.co.in
Registrars
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57, 4th & 5th Floors, Jayabheri Enclave Phase - II, Gachibowli(Old Address:12-10-167, MIG- 167,Bharat Nagar Colony, Hyderabad – 500018.)Phone: +91-40-23818475/6Fax : +91-40-23868024Email: info@vccili Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57 4th & 5th Floors Jayabheri Enclave Phase - II, Gachibowli PIN: Tel No: 23818475,23868257,35164910 Fax No: NULL Email: [email protected] Internet: www.vccipl.com
Management
Chekuri Venkat Ramesh, Company Secretary & Compliance Officer
V C Nannapaneni, Chairman & Managing Director
V C Nannapaneni, Chairman & Managing Director
Rajeev Nannapaneni, Vice Chairman & CEO
PSRK Prasad, Executive Director & Executive Vice President (Corporate Engineering Services)
D Linga Rao, Executive Director & President (Technical Affairs)
ADM Chavali, Non Executive Independent Director
Dronadula Vijaya Bhaskar, Non Executive Independent Director
Kantipudi Suma, Non Executive Independent Director
Nitin Jain, Non Executive Independent Director
Lakshminarayana Bolisetty, Non Executive Independent Director
Details
BSE 524816
NSE NATCOPHARM
ISIN INE987B01026